Anebulo Pharmaceuticals, Inc.
ANEB
$1.36
$0.097.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.31% | 24.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.89% | 7.30% | |||
| Operating Income | 26.89% | -7.30% | |||
| Income Before Tax | 31.94% | -11.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 31.94% | -11.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.94% | -11.92% | |||
| EBIT | 26.89% | -7.30% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 54.57% | -5.77% | |||
| Normalized Basic EPS | 54.63% | -6.04% | |||
| EPS Diluted | 54.57% | -5.77% | |||
| Normalized Diluted EPS | 54.63% | -6.04% | |||
| Average Basic Shares Outstanding | 49.86% | 5.72% | |||
| Average Diluted Shares Outstanding | 49.86% | 5.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||